Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

DRR168574

—

f0e5ba85-5782-5fae-b55a-cede210e18bc

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MTORC1_SIGNALING+0.550
  • G2M_CHECKPOINT+0.540
  • E2F_TARGETS+0.530
  • MYC_TARGETS_V1+0.510
  • INTERFERON_ALPHA_RESPONSE+0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
  • INTERFERON_GAMMA_RESPONSE+0.470
  • HYPOXIA+0.460
  • PANCREAS_BETA_CELLS+0.460
  • ALLOGRAFT_REJECTION+0.450

Top 10 suppressed

  • BILE_ACID_METABOLISM-0.080
  • TGF_BETA_SIGNALING-0.070
  • ESTROGEN_RESPONSE_EARLY-0.060
  • MYOGENESIS-0.060
  • NOTCH_SIGNALING-0.040
  • DNA_REPAIR-0.010
  • ADIPOGENESIS+0.030
  • WNT_BETA_CATENIN_SIGNALING+0.030
  • PEROXISOME+0.050
  • XENOBIOTIC_METABOLISM+0.070

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

6 twins match this tumor's tissue · 4 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MBCProject_1334_T2_RNA
breast-umap@18
—C0.891
2MDT-AP-0428
medullo-epn-umap@date-based
MedMedulloblastoma0.879
3MDT-AP-2865
medullo-epn-umap@date-based
MedMedulloblastoma0.879
4MBCProject_0734_T1B_RNA
breast-umap@18
—C0.878
5TCGA-BH-A0DZ-01A-11R-A00Z-07
breast-umap@18
—C0.878
6MDT-AP-1277
medullo-epn-umap@date-based
MedMedulloblastoma0.877
7TCGA-ZF-A9RD-01A-11R-A42T-07
bladder-landscape@3
——0.875
8DRR168585
bladder-landscape@3
——0.874
9MDT-AP-3087
medullo-epn-umap@date-based
MedMedulloblastoma0.874
10SRR1313165
breast-umap@18
—E0.871

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 44 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MTORC1_SIGNALING0.550Inavolisib— uncovered
G2M_CHECKPOINT0.540Inavolisib— uncovered
E2F_TARGETS0.530Inavolisib— uncovered
MYC_TARGETS_V10.510Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.480Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.470Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.470Idelalisib— uncovered
HYPOXIA0.460Idelalisib— uncovered
PANCREAS_BETA_CELLS0.460Cobimetinib— uncovered
ALLOGRAFT_REJECTION0.450Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.400Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.400Idelalisib— uncovered
PROTEIN_SECRETION0.400Remibrutinib— uncovered
CHOLESTEROL_HOMEOSTASIS0.360Remibrutinib— uncovered
ANDROGEN_RESPONSE0.350Inavolisib— uncovered
COMPLEMENT0.330Inavolisib— uncovered
KRAS_SIGNALING_UP0.330Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.320Idelalisib— uncovered
ANGIOGENESIS0.310Remibrutinib— uncovered
GLYCOLYSIS0.310Inavolisib— uncovered